Kodiak Sciences (KOD) Jefferies London Healthcare Conference 2024 summary

Company overview and strategic direction

• Celebrating 15 years, the organization emphasizes agility and independence, with a late-stage diversified pipeline and global commercial rights.

• Completed six pivotal studies, two more ongoing, and over 2,500 patient years of clinical experience with strong safety data.

• Cash runway supports operations into 2026, with a commercial manufacturing facility in place.

Clinical pipeline and innovation

• Three main programs: tarcocimab, KSI-501, and KSI-101, each targeting BLA submission, with the lead program aiming for filing as early as 2026.

• Enhanced formulations address prior efficacy and safety issues, improving immediacy and manufacturability.

• KSI-501 introduces a bispecific mechanism (IL-6 and VEGF inhibition) for potential improved efficacy in wet AMD.

• KSI-101 targets macular edema secondary to inflammation, aiming for a safer, minimally invasive therapy.

Clinical data and scientific validation

• Human PK data show a mean ocular half-life of 20 days, significantly longer than competitors, supporting six-month dosing durability.

• Pivotal studies in diabetic retinopathy, retinal vein occlusion, and wet AMD demonstrate strong efficacy and durability, with up to 55% of patients achieving six-month durability.

• Enhanced formulation combines conjugated and unconjugated antibody to close the immediacy gap and maintain durability.